These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16845440)

  • 21. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.
    Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W
    Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrathecal therapy with ziconotide: clinical experience and considerations on its use.
    Vitale V; Battelli D; Gasperoni E; Monachese N
    Minerva Anestesiol; 2008 Dec; 74(12):727-33. PubMed ID: 19034250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class.
    Skov MJ; Beck JC; de Kater AW; Shopp GM
    Int J Toxicol; 2007; 26(5):411-21. PubMed ID: 17963128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analgesic effect of highly reversible ω-conotoxin FVIA on N type Ca2+ channels.
    Lee S; Kim Y; Back SK; Choi HW; Lee JY; Jung HH; Ryu JH; Suh HW; Na HS; Kim HJ; Rhim H; Kim JI
    Mol Pain; 2010 Dec; 6():97. PubMed ID: 21172037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziconotide (Prialt) for chronic pain.
    Med Lett Drugs Ther; 2005 Dec 5-19; 47(1223-1224):103-4. PubMed ID: 16331245
    [No Abstract]   [Full Text] [Related]  

  • 27. Spinal antinociception of synthetic omega-conotoxin SO-3, a selective N-type neuronal voltage-sensitive calcium channel blocker, and its effects on morphine analgesia in chemical stimulus tests in rodent.
    Yan LD; Liu YL; Zhang L; Dong HJ; Zhou PL; Su RB; Gong ZH; Huang PT
    Eur J Pharmacol; 2010 Jun; 636(1-3):73-81. PubMed ID: 20361956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
    Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
    Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials.
    Brookes ME; Eldabe S; Batterham A
    Curr Neuropharmacol; 2017; 15(2):217-231. PubMed ID: 26861472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can ziconotide as a N-type voltage-sensitive calcium channel blocker open a new mode for treatment of autism? A hypothesis.
    Ghanizadeh A
    Neurosciences (Riyadh); 2011 Jan; 16(1):83. PubMed ID: 21206454
    [No Abstract]   [Full Text] [Related]  

  • 33. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain.
    Bowersox SS; Gadbois T; Singh T; Pettus M; Wang YX; Luther RR
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1243-9. PubMed ID: 8968347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of human Ca
    Gao S; Yao X; Yan N
    Nature; 2021 Aug; 596(7870):143-147. PubMed ID: 34234349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-type calcium channel blockers: a call for papers.
    Baumrucker SJ
    Am J Hosp Palliat Care; 2005; 22(2):91-2. PubMed ID: 15853084
    [No Abstract]   [Full Text] [Related]  

  • 36. Intrathecal ziconotide for refractory pain.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Jul; 13(7):875-7. PubMed ID: 15212625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature.
    Webster LR
    Pain Med; 2015 Jul; 16(7):1265-77. PubMed ID: 25645109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of spinal substance p release by intrathecal calcium channel blockade.
    Takasusuki T; Yaksh TL
    Anesthesiology; 2011 Jul; 115(1):153-64. PubMed ID: 21577088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term intrathecal ziconotide for chronic pain: an open-label study.
    Webster LR; Fisher R; Charapata S; Wallace MS
    J Pain Symptom Manage; 2009 Mar; 37(3):363-72. PubMed ID: 18715748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Animal Venom Peptides Cause Antinociceptive Effects by Voltage-gated Calcium Channels Activity Blockage.
    Trevisan G; Oliveira SM
    Curr Neuropharmacol; 2022; 20(8):1579-1599. PubMed ID: 34259147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.